NEWS & PR

16 November 2020

Cannabics Pharmaceuticals Founds Digestix Bioscience Inc., a Subsidiary for Treatment of Precancerous and Early Stage Neoplastic Local Tumors

09 November 2020

Cannabics Concludes a Pre-Clinical Study on Human Biopsies in Preparation for FDA pre-IND Meeting Request on Colorectal Cancer Drug Candidate RCC-33

27 October 2020

Cannabics Pharmaceuticals receives “Intention to Grant a European Patent” notice for its System and Method for High Throughput Screening of Cancer Cells patent application

21 October 2020

Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33

06 October 2020

Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers

06 October 2020

Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers

20 August 2020

Cannabics Pharmaceuticals to Establish a Division for its Antitumor Drug Candidate RCC-33

05 August 2020

Cannabics Pharmaceuticals Appoints Dr. Dana Ben-Ami Shor (MD), Gastroenterologist, to its Scientific Board of Advisors

14 July 2020

Cannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets

16 June 2020

Cannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors

26 May 2020

Cannabics Pharmaceuticals to Capitalize on Israel’s Final Approval for the Export of Medical Cannabis

06 May 2020

Cannabics Pharmaceuticals Files Provisional Patent on Composition and Method for Treating Colon Cancer With Cannabinoids

27 April 2020

Cannabics Pharmaceuticals Appoints Prof. Zamir Halpern to Its Scientific Board of Advisors

13 April 2020

Cannabics Pharmaceuticals Develops Novel Cannabis Formulation for the Treatment of Colon Cancer

25 March 2020

Cannabics Pharmaceuticals Study Shows Complex Combinatorial Anti-tumor Activity of Cannabinoids

18 March 2020

Cannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research

11 March 2020

Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma

02 March 2020

Cannabics Pharmaceuticals Reveals Different Extraction Methods Result in Differential Necrotic Effects of Cannabis on Gastrointestinal Cancer Cells

25 February 2020

Cannabics Pharmaceuticals Partners With NewCanna to Commence Research Based on Colombian Indigenous Cannabis Landraces

18 February 2020

Cannabics Pharmaceuticals Study Shows Cannabinoids CBNA and CBCA Cause Necrosis Similarly to their Non-acidic Form

11 February 2020

Cannabics Pharmaceuticals Collaborates With RCKMC to Develop Cannabis Strains Targeting Gastrointestinal Cancers

27 January 2020

Cannabics Pharmaceuticals Study Shows Cannabinoids CBC and CBG Exhibit

09 January 2020

Cannabics Pharmaceuticals Announces Cannabigerol (CBG) Shown to Have Anti-tumor Properties

31 December 2019

Cannabics Pharmaceuticals to be present during the J.P. Morgan Healthcare Conference In San Francisco

05 December 2019

Cannabics Pharmaceuticals Announces the Appointment of Dr. Yaakov Waksman as Head of Cannabidiol Research

16 October 2019

Cannabics Pharmaceuticals Announces Publication of Clinical Data From Its Sponsored Pilot Study on Controlled Release Capsules, on the Journal of Integrative Cancer Therapies

07 October 2019

Cannabics Pharmaceuticals Appoints Company’s Founder to Its Board of Directors

12 September 2019

Cannabics Pharmaceuticals to Present Research Data at the 2nd International Cannabinoid Derived Pharmaceuticals Summit in Boston, MA

28 June 2019

Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments

25 June 2019

Cannabics Pharmaceuticals Appoints Two Independent Directors

04 June 2019

Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada

30 May 2019

Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California Press Release |

17 April 2019

Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies

13 March 2019

OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

12 March 2019

SodaStream CEO Daniel Birnbaum to Join Seedo Board

06 March 2019

Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics

06 March 2019

Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

19 February 2019

Cannabics Pharmaceuticals Submits Protocol for an Ex-Vivo Clinical Study on Biopsies and Cannabinoids

07 February 2019

Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics

07 February 2019

Wize Pharma, Inc. Signs Joint Venture With Cannabics, to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions

31 January 2019

Cannabics Pharmaceuticals Files Four New Provisional Patent Applications for Cannabinoid-Based Drugs and Treatments for Non-Epileptic Seizures and Tremors

24 January 2019

Cannabics Pharmaceuticals and NewCanna Hub Intend to Collaborate to Manufacture and Market Cannabics’ SR Capsules in Colombia

22 January 2019

Cannabics Pharmaceuticals to Co-Sponsor the Canada Cannabis House at the World Economic Forum in Davos

08 January 2019

Cannabics Pharmaceuticals Converts $1 Million Loan Into Common Shares of Seedo

26 December 2018

Cannabics Pharmaceuticals Announces New Provisional Patent Application for Personalized Cannabimetic Compositions Modeling and Production

11 December 2018

Cannabics Pharmaceuticals Prepares ISO Application for Its Diagnostics Platform Towards Commercialization

28 November 2018

Cannabics Pharmaceuticals Received a New Research License for Characterization of Anti-Tumor Activity of Cannabinoids

28 November 2018

Cannabics Pharmaceuticals Announces New Provisional Patent Application for Magnetic Targeting of Cannabinoids

27 November 2018

CEO of Cannabics Pharmaceuticals Presenting at 11th Annual LD Micro Conference, on December 5th, 2018 in LA, California

06 November 2018

Cannabics Pharmaceuticals Inc. CEO talks with Uptick Newswire’s Stock Day Podcast About Cancer Research in the Cannabinoid Sector Press Release |

01 November 2018

CEO of Cannabics Pharmaceutical Speaking at MJBizCon 2018 in Las Vegas

25 October 2018

Cannabics Pharmaceuticals Granted Patent in South Africa for Its Personalized Cannabinoid Based Diagnostics

19 October 2018

Cannabics Pharmaceuticals Announces Attendance at the CannMed 2018 Conference, Held at the UCLA Luskin Conference Center, Los Angeles, October 22-24

16 October 2018

Cannabics Pharmaceuticals Announces Positive Results for Pilot Study on Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

09 October 2018

Join Cannabics Pharmaceuticals at the 3rd CannX Medical Cannabis Conference, Held at Tel-Aviv Convention Center, Israel, October 14-16, 2018

24 September 2018

Cannabics Pharmaceuticals Inc. Prices $7,500,000 Registered Direct Offering

21 September 2018

Cannabics Pharmaceuticals to Present Results of Clinical Trial at International Medical Cannabis Conference

18 September 2018

Eroll Grow Tech (Seedo) Merges Its Activities With GRCR Partners; Cannabics Pharmaceuticals to Own 13.6% in the Merged Company

14 September 2018

Cannabics Pharmaceuticals Receives Positive Results in the Development of Cannabinoid-anticancer Drugs

05 September 2018

Cannabics Pharmaceuticals Granted Patent in Israel for Its Core Technology for Personalized Cannabinoid Based Medicine

28 August 2018

Cannabics Pharmaceuticals Inc. Appoints Dr. Estery Giloz-Ran to Its Advisory Board

22 August 2018

Cannabics Pharmaceuticals Announces That Seedo is to End Pre-Sales and Commence Delivery of Its Automated Growing Devices

14 August 2018

Cannabics Pharmaceuticals Partners with Eroll Grow Tech to Create First Auto-Grow Device for Medical Cannabis

10 August 2018

Cannabics Pharmaceuticals Announces Attendance at the Benzinga Cannabis Capital Conference

09 August 2018

Join Cannabics Pharmaceuticals at the MJBizCon Held at Metro Toronto Convention Center, Toronto, August 14-16, 2018

02 August 2018

Cannabics Pharmaceuticals’ CEO Issues Letter to Shareholders

11 July 2018

Join Cannabics Pharmaceuticals at the National Cannabis Industry Association’s Cannabis Business Summit and Expo Held at San Jose Convention Center, California USA, July 25-27, 2018

03 July 2018

Cannabics Pharmaceuticals Announces Conclusion of Clinical Trial on Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS)

29 June 2018

Cannabics Pharmaceuticals Enters a Memorandum of Understanding With Clinical-Stage Biopharmaceutical Company Focused on the Treatment of Ophthalmic Disorders

26 June 2018

Cannabics Pharmaceuticals to Participate in the International Cannabis Research Society Annual Forum in Leiden, the Netherlands

24 May 2018

Join Cannabics Pharmaceuticals at LCBC Cannabis Professional Conference Held at MTCC, Toronto, Canada, May 25-27, 2018

22 May 2018

Cannabics Pharmaceuticals Hires Two New Scientists to Further Develop Cannabinoid Diagnostic Tests and Treatments for Cancer

02 May 2018

Cannabics Pharmaceuticals Announces Collaboration With Life Source Partners CEO Muriel Zohar to Optimize Technology Applications and Evaluate New Opportunities

18 April 2018

Cannabics Pharmaceuticals Announces New Technology Patent

29 March 2018

Cannabics Pharmaceuticals Receives Positive Results From Preclinical Study on Antitumor Effects of Cannabinoids

28 February 2018

Cannabics’ Dr. Moran Grinberg to Speak at the Annual CannaTech Conference

20 February 2018

Cannabics Pharmaceuticals Hires Chief Data Officer to Address Industry Compliance and Utilization/Analytics Application

02 January 2018

Cannabics Pharmaceuticals Files an International Patent Application on Methods for Testing and Predicting Therapeutic Effectiveness of Cannabinoids for Cancer Patients

08 November 2017

Cannabics Pharmaceuticals Files Patent Application on Cannabinoid Modulation of the Microbiome

25 September 2017

Cannabics Pharmaceuticals Files National Phase Applications for Its System and Method for High Throughput Screening of Cancer Cells

06 September 2017

Cannabics Pharmaceuticals Files a Patent Application for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs

28 August 2017

Cannabics Pharmaceuticals Received Positive Report from The Patent Cooperation Treaty Regarding Cannabinoid Personalized Screening of Cancer Cells

24 July 2017

Cannabics Pharmaceuticals Establishes a Human-Cannabis-Cancer Genetics lab to Expand its Personalized Diagnostics

12 July 2017

Cannabics Pharmaceuticals Executed a Final Collaboration Agreement with SIMFO GmbH

30 June 2017

Cannabics Pharmaceuticals Receives Positive Results in Drug Sensitivity Tests on CTCs

02 June 2017

Cannabics Pharmaceuticals Inc. Provides Shareholders Update June 2017

10 May 2017

Cannabics Pharmaceuticals Raises $3,000,000 in Capital Raise Transaction

03 May 2017

Cannabics Pharmaceuticals Announces Scientific Collaboration With A Leading CTC European Lab

03 April 2017

Cannabics Pharmaceuticals Inc. Receives the Final Report of Its Research on Antitumor Properties of Cannabinoids Held in Israel

09 March 2017

Cannabics Pharmaceuticals Inc. Appoints New Members to its Board of Advisors

23 February 2017

Cannabics Pharmaceuticals Inc. Provides Shareholders Update Regarding Increased Volume in its Shares

07 February 2017

Cannabics Pharmaceuticals Announces Initial Commercialization of Cannabinoids-based Personalized Diagnostics for Cancer Patients

03 January 2017

Cannabics Pharmaceuticals Announces a New Dosage of 5mg THC Cannabis Capsule Treating Cancer Patients Suffering from Cachexia and Anorexia Syndrome

01 December 2016

OTC Markets Group Welcomes Newly Verified OTCQB Companies

01 December 2016

Cannabics Pharmaceuticals Announces Specific Ratios of Cannabinoids Led to Apoptosis in MDA-MB-231 Breast Cancer Cell Viability

06 June 2016

Cannabics Pharmaceuticals has Filed a PCT Application, Covering a Novel Personalized Anti-Cancer Diagnostics System

22 March 2016

Cannabics Pharmaceuticals Announces Start of Clinical Study in Israel for Cancer Patients

29 February 2016

Cannabics Pharmaceuticals Places IP & Subsidiary Within the Company

24 February 2016

Cannabics Pharmaceuticals Files Patent Application for the Company’s Slow Release Capsules

09 October 2015

Cannabics Pharmaceuticals Inc. Announces a New Division of Labor in the Corporate Structure

08 September 2015

Cannabics Pharmaceuticals Inc. Announces New Access of Cannabics Oil Capsules for Patients With Medical Cannabis License in Israel

11 August 2015

OTC Markets Group Welcomes Newly Verified OTCQB Companies

03 August 2015

Cannabics Pharmaceuticals Inc. Announces Increasing Sales of WanaCapsXR Capsules in Every Region of Colorado

21 October 2013

Revocation of BCSC Cease Trade Order

26 August 2011

British Columbia Securities Commission – Cease Trade Order

COMPANY PRESENTATION

image cannabics